Carbene Qubits, Hyperpolarized Sugar, and a $55M Bet from Abbott: How NVision and a Handful of Others Are Building Real Quantum Computing for Healthcare, and Why the Whole Story Comes Down to Energy
Video Preview
🎧 Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Abstract
NVision (Ulm, Germany; founded 2016) closed a $55M Series B on May 13, 2026, anchored by Abbott, with Playground Global, Matterwave/b2venture, Entrée Capital, and a $17M EIB venture loan. Crunchbase logs $38M because that is the equity slice; total raised now $120M. The company runs two products off one physics stack: POLARIS, a room-temperature hyperpolarizer that lifts the MRI signal of sugar molecules by more than 10,000x to image metabolism live; and PIQC, organic carbene qubits printed as 20 to 100 nanometer films onto photonic chips. Coherence already at 2 ms, gates in microseconds, operating at a forgiving 2 to 4 Kelvin. The wider field is real now too: Cleveland Clinic and IBM simulated the 303-atom Trp-cage miniprotein on Heron r2 in March 2026; Qubit Pharmaceuticals and Pasqal placed water in protein pockets on neutral-atom hardware. The through-line, and the actual thesis: a 256-qubit machine draws roughly 7 to 10 kW while Frontier eats about 21 MW, the Landauer limit says irreversible computing wastes energy by a factor near a billion, and the disease being imaged (cancer metabolism, the Warburg effect) is itself an energy accounting problem. Computers and cells run on the same currency. Whoever controls that currency controls both.
Table of Contents
The short version, and why this is not another quantum hype cycle
What NVision actually built, and why the sugar matters as much as the qubit
The carbene gambit, or designing a qubit the way you design a drug
The rest of the room, where real chemistry is getting done
Why this rides behind AI instead of next to it
The part nobody puts on the slide, where energy is the whole ballgame
Landauer, metabolism, and the one currency disease and computers share
What to watch, what to doubt, and where the money goes
The short version, and why this is not another quantum hype cycle
Quantum computing has spent about fifteen years as the technology that is always five years away, which is roughly the credibility profile of a guy who keeps telling you his band is about to get signed. So a healthy reflex when a quantum healthcare headline lands is to assume someone is laundering a physics demo into a press release. That reflex is usually correct. It is also, for the first time in a while, starting to misfire. The reason is that the field quietly split into two populations. One population is still selling the dream of a fault-tolerant machine that cracks chemistry wide open sometime in the next decade. The other population shipped a quantum device into hospitals that are using it today and do not employ a single quantum physicist to operate it. NVision sits in the second group, which is the only group worth a serious operator’s attention right now.
The setup that prompted all this is a Crunchbase card showing a Series B for an outfit listed as NVision Imaging Technologies, $38M, early stage venture, announced mid-May. The actual round is $55M, and the gap is instructive. The company took $38M in equity and stapled on a $17M venture loan from the European Investment Bank, which is the kind of non-dilutive capital you can get when a continent has formally decided your category is strategic. Total raised across the life of the company is now $120M. Abbott led as the sole strategic investor on the diagnostics side, which means a Fortune 500 diagnostics machine just bought a front-row seat rather than a press mention. That detail alone separates this from the usual quantum theater, because Abbott does not write checks to look forward-thinking. Abbott writes checks to own distribution.
What NVision actually built, and why the sugar matters as much as the qubit
